Change search
ReferencesLink to record
Permanent link

Direct link
In vivo clearing of idiotypic antibodies with antiidiotypic antibodies and their derivatives
Umeå University, Faculty of Medicine, Clinical Microbiology.
Umeå University, Faculty of Medicine, Clinical Microbiology.
Umeå University, Faculty of Medicine, Radiation Sciences, Radiation Physics.
Umeå University, Faculty of Medicine, Radiation Sciences, Diagnostic Radiology.
Show others and affiliations
2006 (English)In: Molecular Immunology, ISSN 0161-5890, Vol. 43, no 6, 599-606 p.Article in journal (Refereed) Published
Abstract [en]

At immunolocalization of experimental tumors, idiotypic monoclonal antibodies, such as TS1 against cytokeratin 8, can be used to carry and deposit in vivo terapeutics in the tumor. These carriers also remain in the circulation and may cause negative side-effects in other tissues. In this report, several derivatives of the antiidiotypic antibody alphaTS1 were produced and tested for their clearing capacity of the idiotypic carrier antibody TS1. Intact monoclonal alphaTS1, scFv of a alphaTS1 and alphaTS1 Fab'2 and fragments were produced by recombinant technology or by cleavage with Ficin. The scFv was tailored by use of the variable domain genes of the light and heavy chain from the hybridoma clone in combination with a (Gly4Ser)3-linker, followed by expression in E. coli. When tested for clearing capacity, the intact divalent antiidiotypic IgG was found to be the most efficient. The divalent and the monovalent Fab fragment also demonstrated significant clearing, but lower than the intact antiidiotypic IgG. The alphaTS1 scFv antibody when injected separately was not found to clear the idiotype, but could do so when preincubated with the idiotype. Rapid excretion and in vivo instability of this low molecular weight antibody fragment may be the major reasons. Similar results were obtained when the system was reversed and the 131I-labeled antiidiotype IgG was cleared with the idiotype fragment. It is concluded that both intact antiidiotypic IgG, and Fab'2 fragments are able to clear the idiotypic antibodies. The experimental data support the conclusion that the Fc parts from both the idiotype and the antiidiotype may contribute to this elimination.

Place, publisher, year, edition, pages
2006. Vol. 43, no 6, 599-606 p.
URN: urn:nbn:se:umu:diva-13533DOI: 10.1016/j.molimm.2005.04.019PubMedID: 15978666OAI: diva2:153204
Available from: 2007-02-23 Created: 2007-02-23 Last updated: 2009-12-03Bibliographically approved
In thesis
1. Interaction studies of idiotypic and antiidiotypic antibodies at experimental tumor targeting
Open this publication in new window or tab >>Interaction studies of idiotypic and antiidiotypic antibodies at experimental tumor targeting
2005 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

An increasing number of antibodies are being labeled with radionuclides for immunotargeting, but the negative side effects generated on normal tissues by the nuclide remains a significant problem. The clearing of non-tumor-targeted radiolabeled antibodies from the circulation contributes significantly to improved targeting; it has been demonstrated that anti-idiotypic antibodies can be used for this purpose. This thesis describes a study of the interactions between the idiotypic antibody TS1, its intracellular tumor-associated antigen CK8 and anti-idiotypic antibody aTS1 as well as the clearing and metabolism of the complexes formed between TS1 and aTS1.

The TS1 epitope on CK8, located at amino acid positions 347–348, 350, 354–355, and 357 in helix 2B, was identified through alanine scanning. Upon chemical modification of TS1 using protective and unprotective approaches, it became apparent that the TS1 interaction sites for aTS1 and CK8 were partially overlapping. Aspartic acid, glutamic acid, and tyrosine residues and primary amino groups are important for the interactions of TS1 with both CK8 and aTS1. One modification of acidic amino acids in TS1 increased the affinity for CK8. Furthermore, TS1 contains one histidine residue that is located in a groove of the interaction surface and, from chemical modification studies; this histidine residue appears to play an important role for the interaction only with aTS1. Using phage display technology, specifically binding peptides having homologies with aTS1 were selected against TS1; site-directed mutagenesis verified the importance of two histidines, one valine, and one tyrosine residue in the homologous region of the light chain of aTS1. Site-directed mutagenesis also demonstrated that Y32 and K50 in the light chain and K33 and Y52 in the heavy chain positioned centrally on the antibody combining site of aTS1 were crucial for the binding to TS1. Two aTS1 mutants having affinities for TS1 similar to that of the wild type, but having faster association and dissociation rate constants, were identified.

The clearing capacity of the monoclonal aTS1IgG wild type was studied in vivo in non-tumor-bearing mice. At a molar ratio of TS1:aTS1 of 1:1.2, the whole-body radioactivity decreased by 85%; this value compares to the 25% reduction observed for the control, which received no aTS1. The metabolism of the complex formed between TS1 and aTS1 in vivo was also investigated; most of the degradation occurred in the liver. The complexes formed between TS1 and aTS1 were studied using electron microscopy, which indicated that ring structures of four, six, or eight antibodies were preferred; dimers were rare. ScFv, Fab, and Fab´2 fragments of aTS1 were generated and their abilities to clear the circulation from radiolabeled TS1 in vivo in non-tumor-bearing mice were studied. IgG was the most efficient clearing agent; Fab´2 and Fab displayed lower, but significant, clearing abilities. The scFv:s provided a slight degree of clearing if preincubated with TS1.

The results presented in this Thesis demonstrate that it is possible to engineer the properties of antibodies to make them suitable for use in immunotherapy.

Place, publisher, year, edition, pages
Umeå: Klinisk mikrobiologi, 2005. 78 p.
Umeå University medical dissertations, ISSN 0346-6612 ; 974
anti-idiotypic antibody, clearing, cytokeratin 8, epitope, idiotypic antibody, immunotherapy
urn:nbn:se:umu:diva-583 (URN)91-7305-905-6 (ISBN)
Public defence
2005-09-19, Sal A103, Astrid Fagraeussalen, By 6, Norrlands Universitetssjukhus, Umeå, 09:00 (English)
Available from: 2005-09-05 Created: 2005-09-05 Last updated: 2009-11-12Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Eriksson, DavidJohansson, LennartRiklund, KatrineStigbrand, Torgny
By organisation
Clinical MicrobiologyRadiation PhysicsDiagnostic Radiology
In the same journal
Molecular Immunology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 42 hits
ReferencesLink to record
Permanent link

Direct link